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ABSTRACT
Background: Female participants in AIDS candidate vaccine clinical trials must agree 
to use effective contraception to be enrolled into the studies, and for a specified period 
after vaccination, since the candidate vaccines’ effects on the embryo or foetus are 
unknown. 
Objectives: To review data on female participants’ pregnancy rates from phase I and 
IIA AIDS vaccine clinical trials conducted at the Kenya AIDS Vaccine Initiative (KAVI) 
and to discuss the challenges of contraception among female participants. 
Design: Descriptive observational retrospective study. 
Setting: KAVI clinical trial site, Kenyatta National Hospital and University of Nairobi, 
Kenya. 
Subjects: Thirty nine female participants were enrolled into these trials. They received 
family planning counselling and were offered a choice of different contraceptive 
methods, as per the protocols. All contraception methods chosen by the participants 
were offered at the study site at no cost to the participant. 
Results: Four women conceived during the study period when pregnancies were to be 
avoided. All four had opted for sexual abstinence as a contraceptive method, but reported 
having been coerced by their partners to have unprotected sexual intercourse. 
Conclusion: Abstinence is clearly not a reliable contraceptive option for women in 
developing-country settings. Effective female-controlled contraceptives, administered 
at the clinical trial site, may empower female participants to better control their fertility, 
leading to more complete clinical trial data. 
INTRODUCTION
It is generally believed that a safe and efficacious 
preventive AIDS vaccine is one of the best long-
term hopes to control and eventually eliminate the 
HIV/AIDS pandemic (1). Of the 2.7 million new HIV 
infections that occur globally annually, more than 
half occur in women (2), and in many countries HIV 
prevalence among women has surpassed that among 
males in the sexually active age groups. 
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 HIV prevention among women faces many 
challenges. These challenges include the need for 
women to bear children; culturally defined gender 
roles and power dynamics that disempower women 
and constrain them from negotiating safe sex; lower 
economic and social power compared to men; and 
lack of access to health care, among others (3). The 
development of a preventive AIDS vaccine is therefore 
a high priority as a fully self-controlled preventive 
method. 
 Clinical trials testing AIDS candidate vaccines 
require the participation of both males and females 
in equitable numbers for several reasons (4). Firstly, 
researchers need to determine a candidate vaccine’s 
safety and efficacy in both genders. As women 
and men are physiologically different, results and 
conclusions of vaccine efficacy and/or side effects 
from only one gender cannot be extrapolated to 
the other; indeed, recent findings suggest that HIV 
pathology may differ based on gender and route 
of infection (5). Secondly, licensure requires testing 
in fully representative populations. And thirdly, 
participants in AIDS vaccine research benefit from 
risk- reduction education, counselling and care; 
excluding women who are eligible to participate 
would not only be discriminatory, but would also be 
unethical based on the principle of equity (3, 4, 6). 
 However, despite the importance of female 
participation in AIDS vaccine clinical trials, many 
researchers have, for diverse reasons, experienced 
difficulties recruiting women (4). 
 Female participants in AIDS vaccine clinical 
trials must use effective contraception during and 
for a period after vaccination, because the candidate 
vaccine’s effects on the embryo or foetus are 
unknown. If a female participant conceives during 
the vaccination period, further vaccinations will 
not be given, which compromises the completeness 
of data and information gained from the trial. This 
circumstance further erodes the already diminished 
contribution of female participation in AIDS vaccine 
clinical trials. Every effort must therefore be made to 
ensure that female participants in such trials do not 
become pregnant during the specified period and 
that they are retained to the trial’s conclusion. 
 Here, we present pregnancy data from four AIDS 
vaccine clinical trials conducted since 2001 at the Kenya 
AIDS Vaccine Initiative (KAVI) research centre based 
at the University of Nairobi’s School of Medicine, 
in Nairobi, Kenya. We make recommendations that 
would reduce the incidence of pregnancy in future 
clinical trials. 
MATERIALS AND METHODS
Three Phase 1 trials were conducted between 2001 and 
2004, testing (i) an HIV clade A plasmid DNA (DNA.
HIVA) vaccine (Protocol IAVI 002), (ii) a recombinant 
vaccine vectored by modified vaccinia virus Ankara 
(MVA; MVA.HIVA) (IAVI 004), and (iii) DNA.HIVA 
as prime followed by MVA.HIVA as boost (IAVI 010). 
Phase IIA trial was conducted between 2005 and 2007 
testing the VRC recombinant replication-defective 
Adenovirus sub-type 5-vectored multiclade vaccine 
(Vaccine Research Centre (VRC), NIH, VRC HIV-1 
rAd5) either alone or as boost following VRC HIV-1 
DNA vaccine (IAVI VRC V001). The Phase IIA trial 
was conducted prior to the outcome of the STEP trial, 
a test-of-concept trial of a different Adenovirus sub-
type 5-vectored HIV vaccine developed by Merck 
Pharmaceuticals (7). 
 In all trials, participants were selected based 
on their self-reported low risk of HIV infection. 
For eligibility, participants were required to report 
that in the six months preceding enrolment they 
had not had unprotected vaginal or anal sex with 
a known HIV-infected person or a casual partner, 
had not engaged in sex work for money or drugs, 
had not used injection recreational drugs and had 
not had a sexually transmitted disease. To maintain 
confidentiality, the trial team did not inform 
participants’ spouses about their participation in the 
trial. This responsibility was left to the discretion of 
the participants themselves. 
 Comprehensive family planning counselling, 
including contraceptive options, was discussed with 
all female participants in one-on-one sessions with 
trained nurse counsellors at every visit. Each female 
participant was then asked to select one contraceptive 
method of her choice, except in the first trial 
conducted in KA VI (IAVI 002), in which all the female 
participants were required to use an oral contraceptive 
(Microgynon®). The other contraceptive methods 
offered were the intrauterine contraceptive device 
(copper-T®), injectable hormonal contraceptive 
(Depo-provera ®), consistent male condom use and 
sexual abstinence. In all trials, the chosen family 
planning method was initiated at screening, which 
was up to six weeks before enrolment into the study. 
Based on screening results, participants were then 
enrolled into the trial. Family planning counselling 
sessions were conducted at each protocol visit. 
 Female participants were required not to become 
pregnant for specific periods: In the DNA.HIVA and 
the MVA.HIVA trials, this period was within four 
months after the last vaccination. In the DNA.HIVA 
prime/MVA.HIVA boost trial the period was within 
six months after the last vaccination, and in the VRC 
DNA prime/rAd5 boost trial, participants were 
prohibited from becoming pregnant for 18 months, 
that is, to the end of the trial. 
 Approvals to conduct the trials were obtained 
from Kenyatta National Hospital Ethics and Research 
Committee, Pharmacy and Poisons Board, University 
of Nairobi Institutional Biosafety Committee and 
National Council for Science and Technology. 
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RESULTS
In total, 163 participants at self-reported low risk 
for HIV infection have participated in the four AIDS 
vaccine clinical trials conducted at KAVI since 2001, 
of whom 39 (23.9%;) were females (Table 1) aged 
between 18 and 48 years (median age 23 years). 
 Thirteen percent (5/39) of the female participants 
had a university education, 74% (29/39) had 
secondary-level education (9-12 years of school), and 
13% (5/39) had primary education (up to 8 years of 
formal school attendance). Thirty-one of the female 
participants were single, six were married and two 
were divorced. 
Figure 1 and Table 1 show the distribution of 
contraceptive methods used by all the female 
participants during the four HIV vaccine trials 
at KAVI. The most commonly used methods of 
contraception were oral hormonal contraceptives 
(31%), sexual abstinence (26%) and injectable hormonal 
contraceptives (23%).  Table 2 shows the number of 
female participants who became pregnant in each 
of the trials. No participant in protocols IAVI 002 or 
IAVI 004 became pregnant during the period when 
pregnancy was not allowed according to the protocol. 
One of 12 participants in protocol IAVI 010 became 
pregnant, and three of the 22 female participants 
in protocol IAVI VRC V001 became pregnant. This 
Oral contraceptives 31% (n=12)




None (menopousal) 3% (n=2)
Male condoms 5% (n=2)
Table 1
Number of female participants in the four HIV vaccine clinical trials at the KAVI site, and contraceptive methods 
used
Trial No. of female OC Norplant IUCD IHC Abstinence MC Menopausal 
 volunteers/Total
 No. of volunteers
DNA (IAVI 002) 3/18 3 0 0 0 0 0 0 
MVA (IAVI 004) 2/18 1 1 0 0 0 0 0
DNA prime/MVA 
boost (IAVI 010) 12/70 4 2 0 3 3 0 0
DNA prime/rAd5 
boost (IAVI VRC V001) 22/57 4 1 1 6 7 2 1
Total 39/166 12 4 1 9 10 2 1
OC = Oral contraceptives 
IUCD = Intrauterine contraceptive devices 
IHC = Injectable hormonal contraceptives 
MC = Male condoms 
Figure 1
Contraceptive methods used by all female participants in HIV vaccine clinical trials at KAVI, Nairobi
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represents a pregnancy rate of 8.3 and 13.6% in trials 
with 12 and 22 female participants respectively. All the 
four female participants who became pregnant were 
single, with three of them being primigravida and 
the fourth having had one live birth with no history 
of miscarriages. All of these women had also chosen 
sexual abstinence as their contraception method. 
However, they all reported having been coerced by 
their partners to have unprotected sex. Table 2 also 
shows the period during the protocol in which the 
four participants became pregnant. 
DISCUSSION
The participation of females in AIDS vaccine clinical 
trials testing is crucial, as it is the only way to 
determine the effects of candidate vaccines in women, 
and to detect any difference in the candidate vaccines’ 
activity in males and females (4). 
 Recruiting female participants has been an 
ongoing challenge at our trial site; only 39 (22%) 
women were enrolled out of the total of 163 
participants in the four clinical trials conducted at 
KAVI since 2001. Although some studies have shown 
women’s willingness to participate in AIDS vaccine 
clinical trials (8), minimal participation of women in 
such trials has been observed at other sites as well, 
and in all phases of HIV vaccine clinical trials (4).
 Possible barriers specific to female participation 
in AIDS vaccine clinical trials include the strict 
contraceptive requirements and concerns for the 
safety of the embryo and foetus. Women may also be 
concerned about the outcome of future pregnancies 
after participating in such trials (5). The partners 
of female trial participants may refuse sexual 
intercourse due to the woman’s involvement in a 
trial. Furthermore, a lack of convenient clinic hours 
for mothers, domestic workers and sex workers 
(3) presents an additional barrier to women’s 
participation. In many cultures, women are not able 
to make decisions to participate in such trials without 
their spouse’s permission (4, 5). 
 Enrolment in AIDS vaccine trials by both 
men and women may also be hindered by public 
misunderstanding about the risk of contracting 
HIV from candidate vaccines. Furthermore, a false-
positive antibody test could lead to a participant being 
mistakenly viewed as HIV-infected, and facing social 
stigma and discrimination as a consequence. 
 Concerns about unknown effects of any 
investigational agent on an embryo and foetus, and 
potential risks to the future reproductive capacity of 
female participants (9) demands that pregnant women 
be excluded from enrolling into trials of investigational 
new drugs, and women of reproductive potential are 
expected to use contraception during such trials (10). 
AIDS candidate vaccine trials are no exception. Thus, 
occurrence of pregnancies among female participants 
in AIDS candidate vaccine clinical trials further 
reduces female participation by reducing the number 
of women from whom complete information about a 
candidate vaccine can be obtained, since vaccination 
has to be stopped when a pregnancy occurs. The 
issue of contraception thus needs to be addressed 
if meaningful data from female participants in such 
trials are to be obtained. Otherwise, high pregnancy 
rates should be taken into consideration when the 
sample size is being determined (10). 
 In our trials, the female participants were mostly 
young, single and in the reproductive age group. The 
requirement to avoid pregnancy during a specified 
period presented a challenge, even with regular family 
planning counselling prior to enrolment and during 
each protocol visit. The situation is compounded by 
the fact that many women in developing-countries 
settings are not in a position to choose a contraceptive 
method without their partner’s permission. 
 A previous review of safety data from 25 Phase 
I and Phase II AIDS vaccine clinical trials involving 
low-risk female participants found a pregnancy rate 
of 2.9% (11). The higher pregnancy rate at our site may 
be attributable to the fact that female participants at 
our site were younger than those reported in this 
review. Additionally, the higher pregnancy rate seen 
in our trials compared to that in the reported studies 
may have been due to differences in contraception 
methods used by our female participants and those 
in the studies reviewed. Some of the participants in 
our trials used sexual abstinence as their preferred 
contraceptive method, while in the reviewed studies 
abstinence was not an approved contraceptive 
option. 
 A high pregnancy incidence has also been noted 
among high-risk women participating in a HIV 
vaccine efficacy trial (9). In this trial lasting three years, 
pregnancy incidence was calculated on the basis of 
person-years of follow-up. Published preliminary 
pregnancy incidence over the first 18 months of this 
study was 4.6 per 100 person years (9). Those who 
became pregnant were more likely to be less than 35 
years and at baseline reported unprotected sex in the 
previous six months. It may however be expected 
of women at high risk of acquiring HIV to also have 
a higher pregnancy rates therefore negating the 
comparison of the rates in populations with different 
risks of HIV acquisition. 
 All the women who became pregnant in our trials 
were single and mostly primigravida. They had all 
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elected to use sexual abstinence as a contraception 
method, but evidently engaged in unprotected 
sex. Although we did not see pregnancies among 
the two participants who reported consistent use 
of male condoms by their sexual partners, this 
observation may be due to the small sample size. Male 
condoms usage is likely to have drawbacks similar 
to abstinence, as their effective use largely depends 
on the co-operation of the sexual partners. The use 
of effective female-controlled contraceptives in trials 
would go along way towards ensuring that all females 
enrolled complete the trial, and that sufficient data 
are gathered to allow quantitative analyses. 
In conclusion, our data indicate that despite repeated 
family planning counselling, female participants 
in AIDS candidate vaccine clinical trials in Kenya 
experienced difficulty in preventing pregnancy 
when their chosen family planning method was 
sexual abstinence even though they were single. We 
recommend therefore that sexual abstinence should 
not be allowed as an option in future clinical trials. 
 Efficacious and long-acting female-controlled 
contraceptive methods, administered at the clinical 
trial site, should be offered instead. 
ACKNOWLEDGEMENTS
We thank all the volunteers who participated in 
these trials. We also thank the staff at KAVI for the 
splendid work done and Daisy Ouya for reviewing 
the manuscript and making valuable comments and 
suggestions. All the AIDS vaccine clinical trials at 
KAVI were funded by the International AIDS Vaccine 
Initiative (IAVI). IAVI 010 trial was conducted jointly 
with St. Thomas Hospital in London, while IAVI VRC 
V001 trial was conducted jointly with Project San 
Francisco (PSF) site in Kigali, Rwanda. 
Conflict of Interest: The authors Patricia Fast, Claudia 
Schmidt and Carl Verlinde are either employees or 
consultants of IAVI, the funding organisation and 
have no commercial interest or other association that 
might raise a conflict of interest. 
REFERENCES
1. Rudy, E.T., Newman, P.A., Duan, N.  et al. HIV vaccine 
acceptability among women at risk: Perceived barriers 
and facilitators to future HIV vaccine uptake. AIDS 
Education and Prevention. 2005; 17:253-267. 
2.  UNAIDS/WHO Joint United Nations Programme on 
HIV/AIDS. AIDS epidemic update: UNAIDS 2007, 
Geneva, Switzerland. http://www.unaids.org. 
3. Mills, E., Nixon, S., Singh, S. et al. Enrolling women into 
HIV preventive vaccine trials: an ethical imperative but 
a logistical challenge. PloS Medicine. 2006; 3:3 e94. 
4. WHO-UNAIDS Expert Group. Gender, age, and 
ethnicity in HIV vaccine-related research and clinical 
trials, report from a WHO-UNAIDS consultation, 26-
28 August 2004. Lausanne, Switzerland. AIDS. 2005; 
19:w7-28. 
5. UNAIDS/WHO (2007b) Ethical consideration in 
biomedical HIV prevention trials. UNAIDS(2007). 
http://data.unaids.org/pub/Reportl2007/iG1399-eth 
icalconsiderations en.pdf. 
6. Sheon, A.R., Wagner, L., McElrath, M.J., et al. 
Preventing discrimination against volunteers in 
prophylactic HIV vaccine trials. Lessons from a phase 
II trial. J. Acq. Immuno. Syndr. Hum. Retr. Infect. 1998; 
19:519-526. 
7. Buchbinder, S.P., Mehrotra, D.V., Duerr, A., et al. Step 
Study Protocol Team. Efficacy assessment of a cell-
mediated immunity HIV-1 vaccine (the Step Study): 
a doubleblind, randomised, placebo-controlled, test-
of-concept trial. Lancet. 2008; 372: 1881-1893. 
8. Kiwanuka, N., Robb, M., Kigozi, G., et al. Knowledge 
about vaccines and willingness to participate in 
preventive HIV vaccine trials: a population-based 
study, Rakai, Uganda. J. Acq. Immune. Defic. Syndr. 
2004; 36:721-725. 
9. Brown-Peterside, P., Ren, L., Hirsch, A., et al and the 
Vaxgen Study Team Pregnancies, among high-risk 
women in the first ever HIV vaccine efficacy trial. 
AIDS. 2003; 17: 787-788. 
10. Bennett, J.C. Inclusion of women in clinical trials - 
policies for population subgroups. New Engl. J. Med. 
1993; 329:288-292. 
11.  Keefer, M.C., Wolff, M., Gorse, G.J., et al. and the 
NIAD AIDS Vaccine Evaluation Group. Safety profile 
of phase I and II preventive HIV type envelope 
vaccination: experience of the NIAD AIDS Vaccine 
Evaluation Group. AIDS Res. Human Retroviruses. 
1997; 13:1163-1177. 
